CDXC 4.8: Small Float Biotech backed by Li Ka Shing

In this market where SPEC trades at billions with NO revenue, I like CDXC though I may be early. Yes it's not TSLA, yes Value does not work in this market but

With a tiny market cap of 290 mil and revenue growth at 40% (still early-stage market), I am betting with Li Ka Shing, one of the richest and other top 20 institutions including Blackrock who collectively owns 55% of the stock. Short interest is small at 7%.

The better story is that the stock has been basing for a long time, and technicals are improving. I don't want to wait for breakout then buy as by then I would be paying too much a premium. So good enough for me with the IMPROVING technicals and a largely positive trend, and a real growth story.

investors.chromadex.com/news/news-details/2018/ChromaDex-Announces-Strategic-Partnership-for-Aging-Research-with-Jiangxi-Government-in-China/default.aspx

asia.nikkei.com/Business/Health-Care/Nobel-prizes-highlight-Li-Ka-shing-s-role-in-scientific-research

Top Shareholders
Top 25 shareholders own 54.62% of the company
Ownership Name Shares Current Value Change % Portfolio %
10.49%
Ka-shing Li 6,500,937 $31.4m 0% no data
10.29%
Hoi Shuen Chau 6,377,783 $30.8m 0% no data
4.53%
BlackRock, Inc. 2,804,544 $13.5m -0.81% no data
3.97%
The Vanguard Group, Inc. 2,461,485 $11.9m 9.03% no data
3.8%
Li Ka Shing (Global) Foundation, Endowment Arm 2,353,139 $11.4m 0% 3.25%
3.11%
Phillip and Patricia Frost Philanthropic Foundation, Inc, Endowment Arm 1,929,542 $9.3m 0% 42.91%
2.76%